SURFACE LOGIX APPOINTS SENIOR VP OF COMMERCIAL DEVELOPMENT
BOSTON, Mass. (February 17, 2005) - Surface Logix is pleased to announce the appointment of Dr. Warwick Tong as Senior Vice President, Commercial Development. As a member of the executive team, Dr. Tong will primarily be responsible for driving the commercial input into the selection and direction of the drug development programs at Surface Logix. Dr. Tong will also help drive key business relationships with thought leaders and potential partners in the therapeutic areas of interest for the company.
"I am extremely pleased to welcome Warwick to the Surface Logix executive team. I look forward to working with him as we build on the success of our PharmacomerTM Technology Platform and push forward into the clinic with the drug development programs that have resulted from the application of this technology," said Jim Mahoney, CEO of Surface Logix. "Warwick’s medical background combined with his 12 years of broad pharmaceutical industry experience in commercial and clinical development brings a valuable mix of skills and experience to our company as we take our first drugs into clinical development.”
Prior to Surface Logix, Dr. Tong worked as Vice President, Strategy and Redesign with GlaxoSmithKline, leading a major redesign program in the late stage development organization following the merger of Glaxo Wellcome and Smith Kline Beecham. Previously, Dr Tong led the global commercial strategy group for anti-infectives in Glaxo Wellcome following a period as the Regional Business Development Director for the Asia Pacific Region. Dr Tong originally joined Glaxo in New Zealand as a Medical Director after a number of years in clinical medicine with interests in primary care and drug dependency.
Dr. Tong received his medical degree (MB ChB) from Auckland University Medical School in New Zealand and has a Masters in Public Policy from Victoria University in Wellington, New Zealand.
Surface Logix is a drug development company that creates new therapeutics by significantly improving the pharmacokinetic (PK) and pharmacodynamic (PD) properties of approved drugs and late stage compounds. The company uses its proprietary small molecule Pharmacomer™ Technology to chemically modify drugs and late stage compounds to create New Chemical Entities (NCEs) with improved bioavailability and tissue distribution profiles. Surface Logix also combines its Pharmacomer™ Technology with nanotechnology capabilities to create miniaturized assays to test the interaction of biological molecules with potential drug candidates. These assays serve as ex-vivo models to evaluate and fine-tune the oral bioavailability, membrane permeability, metabolism, and distribution characteristics of NCEs. Surface Logix has several drugs in clinical and preclinical development. For more information on our programs please visit our website at www.surfacelogix.com
back |
